Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Budesonide/formoterol (BDF) vs placebo

Adverse events—'serious'—320/94 Duration of 10 months3 · COPD

Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.17 [0.95, 1.45]
2476 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse events—'serious'—160/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.2 [0.89, 1.63]
1556 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse event—any—320/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) may leads to higher adverse event—any—320/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.42 [1.16, 1.74]
1552 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse event—any—160/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) may leads to higher adverse event—any—160/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.32 [1.08, 1.61]
1556 participants
Low

Intervention not reported

Adverse events－serious events Budesonide/formoterol (BDF) versus budesonide (BD) · patients with COPD

It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus inhaled corticosteroids alone for chronic… 2013 · Cochrane Headline outcomes only
OR 0.93 [0.72, 1.21]
3 studies · 1469 participants
Very low